Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05054439Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izalontamab in head and neck squamous cell carcinoma (HNSCC), sponsored by Biokin Pharmaceutical. Primary endpoint: Objective Response Rate up to 2 years. Started Dec 2021; status: active, not recruiting.
02
Drugs
izalontamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05054439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054439.